Specific 12β-hydroxylation of cinobufagin by filamentous fungi

Applied and Environmental Microbiology

Volumn 70, Issue 6, 2004, Pages 3521-3527

  Ye, Min ^a   Qu, Guiqin ^a   Guo, Hongzhu ^a   Guo, Dean ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLUMN CHROMATOGRAPHY; DEHYDROGENATION; DRUG PRODUCTS; FERMENTATION; HYDROXYLATION; LIQUID CHROMATOGRAPHY; METABOLISM; SYNTHESIS (CHEMICAL);

BIOTRANSFORMATION; STEROIDS;

FUNGI;

12 OXOCINOBUFAGIN; 12BETA HYDROXYLCINOBUFAGIN; 12BETA HYDROXYLDESACETYLCINOBUFAGIN; 3 OXO 12ALPHA HYDROXYLCINOBUFAGIN; 3 OXO 12BETA HYDROXYLCINOBUFAGIN; BUFADIENOLIDE DERIVATIVE; CINOBUFAGIN; DRUG METABOLITE; SILICA GEL; UNCLASSIFIED DRUG;

BIOTECHNOLOGY; BIOTRANSFORMATION; FUNGUS;

ABSIDIA; ALTERNARIA; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS NIGER; BIOTRANSFORMATION; CARBON NUCLEAR MAGNETIC RESONANCE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; CUNNINGHAMELLA; CYTOTOXICITY; DEACETYLATION; DEHYDROGENATION; DRUG HYDROXYLATION; FERMENTATION; FUNGUS; HEPATOMA CELL; HUMAN; HUMAN CELL; MUCOR; NONHUMAN; PENICILLIUM JANTHINELLUM; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSED PHASE LIQUID CHROMATOGRAPHY; SPOROTHRIX;

ALTERNARIA; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; BUFANOLIDES; CARBON ISOTOPES; CELL LINE, TUMOR; HUMANS; HYDROXYLATION; MAGNETIC RESONANCE SPECTROSCOPY;

ABSIDIA; ALTERNARIA; ALTERNARIA ALTERNATA; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS NIGER; CUNNINGHAMELLA; FUNGI; MAMMALIA; MUCOR; PENICILLIUM; PENICILLIUM JANTHINELLUM; SPOROTHRIX;

EID: 2942554874     PISSN: 00992240     EISSN: None     Source Type: Journal    
DOI: 10.1128/AEM.70.6.3521-3527.2004     Document Type: Article

References (33)

1. Abourashed, E. A., A. M. Clark, and C. D. Hufford. 1999. Microbial models of mammalian metabolism of xenobiotics: an updated review. Curr. Med. Chem. 6:359-374.
2. Azerad, R. 1999. Microbial models for drug metabolism, p. 169-218. In T. Scheper (ed.), Advances in biochemical engineering/biotechnology, vol. 63. Biotransformations. Springer-Verlag, Berlin, Germany. Biotechnol. 63:169-218.
3. Carmichel, J., W. G. DeGraff, A. F. Gazdar, J. D. Minna, and J. B. Mitchell. 1987. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:936-942.
4. Cirino, P. C., and F. H. Arnold. 2002. Protein engineering of oxygenases for biocatalysis. Curr. Opin. Chem. Biol. 6:130-135.
5. Clark, A. M., and C. D. Hufford. 1991. Use of microorganisms for the study of drug metabolism: an update. Med. Res. Rev. 11:473-501.
6. Farooq, A. H., R. James, and Z. Iqbal. 1994. Hydroxylation of progesterone by Cephalosporium aphidicola. Phytochemistry 37:723-726.
7. Goerlich, B. 1971. Transformation of scillarenin with Rhizopus arrhizus I. Structural determination of the Rhizopus arrhizus-induced transformation products of scillarenin II. Planta Med. Suppl. 5:113-126. (In German.)
8. Goodhue, C. T. 1982. The methodology of microbial transformation of organic compounds, p. 9-44. In J. P. Rosazza (ed.), Microbial transformations of bioactive compounds, vol. I. CRC Press, Boca Raton, Fla.
9. Hashimoto, S., Y. Jing, N. Kawazoe, Y. Masuda, S. Nakajo, T. Yoshida, Y. Kuroiwa, and K. Nakaya. 1997. Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs. Leuk. Res. 21:875-883.
10. Hong, Z., K. Chan, and H. W. Yeung. 1992. Simultaneous determination of bufadienolides in the traditional Chinese medicine preparation, Liu-Shen-Wan, by liquid chromatography. J. Pharm. Pharmacol. 44:1023-1026.
11. Horiger, N., D. Zivanov, H. H. A. Linde, and K. Meyer. 1972. Weitere bufadienolide aus Ch'an Su. Helv. Chim. Acta 55:2549-2562. (In German.)
12. Jezequel, S. G. 1998. Microbial models of mammalian metabolism: uses and misuses (clarification of some misconceptions). J. Mol. Catal. B Enzym. 5:371-377.
13. Kamano, Y., A. Kotake, H. Hashima, M. Inoue, H. Morita, K. Takeya, H. Itokawa, N. Nandachi, T. Segawa, A. Yukita, K. Saitou, M. Katsuyama, and G. R. Pettit. 1998. Structure-cytotoxic activity relationship for the toad poison bufadienolides. Bioorg. Med. Chem. 6:1103-1115.
14. Kamano, Y., A. Yamashita, T. Nogawa, H. Morita, K. Takeya, H. Itokawa, T. Segawa, A. Yukita, K. Saito, M. Katsuyama, and G. R. Pettit. 2002. QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5. J. Med. Chem. 45:5440-5447.
15. Krenn, L., and B. Kopp. 1998. Bufadienolides from animal and plant sources. Phytochemistry 48:1-29.
16. Linde, H. H. A., and F. Lohrer. 1991. Strukturaufklarung von Gamabufotaliniol (1). Pharm. Acta Helv. 66:98-101.
17. Loughlin, W. A. 2000. Biotransformations in organic synthesis. Bioresour. Technol. 74:49-62.
18. Mahato, S. B., and S. Garai. 1997. Advances in microbial steroid biotransformation. Steroids 62:332-345.
19. Masuda, Y., N. Kawazoe, S. Nakajo, T. Yoshida, Y. Kuroiwa, and K. Nakaya. 1995. Bufalin induces apoptosis and influences the expression of apoptosis-related genes in human leukemia cells. Leuk. Res. 19:549-556.
20. Nogawa, T., Y. Kamano, A. Yamashita, and G. R. Pettit. 2001. Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su. J. Nat. Prod. 64:1148-1152.
21. Preisig, C. L., J. A. Laakso, U. M. Mocek, P. T. Wang, J. Baez, and G. Byng. 2003. Biotransformations of the cardiovascular drugs mexrenone and canrenone. J. Nat. Prod. 66:350-356.
22. Riva, S. 2001. Biocatalytic modification of natural products. Curr. Opin. Chem. Biol. 5:106-111.
23. Steyn, P. S., and F. R. van Heerden. 1998. Bufadienolides of plant and animal origin. Nat. Prod. Rep. 15:397-413.
24. 450 monooxygenases. Curr. Opin. Biotechnol. 13:557-564.
25. Voigt, B., A. Porzel, H. Naumann, S. C. Hoerhold, and G. Adam. 1993. Hydroxylation of the native brassinosteroids 24-epicastasterone and 24-epibrassinolide by the fungus Cunninghamella echinulata. Steroids 58:320-323.
26. Yang, X. W., Z. T. Xing, J. R. Cui, Y. L. Fan, R. Zhao, and X. G. Li. 2001. Studies on the metabolism of cinobufagin and cinobufotalin by human intestinal bacteria. J. Peking Univ. (Health Sci.) 33:199-204. (In Chinese.)
27. Ye, M., J. Dai, H. Guo, Y. Cui, and D. Guo. 2002. Glucosylation of cinobufagin by cultured suspension cells of Catharanthus roseus. Tetrahedron Lett. 43:9535-8538.
28. Ye, M., J. Han, H. Guo, and D. Guo. 2002. Structural determination and complete NMR spectral assignments of a new bufadienolide glycoside. Magn. Reson. Chem. 40:786-788.
29. Ye, M., L. Ning, J. Zhan, H. Guo, and D. Guo. 2003. Biotransformation of cinobufagin by cell suspension cultures of Catharanthus roseus and Platycodon grandiflorum. J. Mol. Catal. B Enzymol. 22:89-95.
30. Yeh, J. Y., W. J. Huang, S. F. Kan, and P. S. Wang. 2003. Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 54:112-124.
31. Zhang, L. S., K. Nakaya, T. Yoshida, and Y. Kuroiwa. 1991. Bufalin as a potent inducer of differentiation of human myeloid leukemia cells. Biochem. Biophys. Res. Commun. 178:686-4393.
32. Zhang, L. S., T. Yoshida, K. Aoki, and Y. Kuroiwa. 1991. Metabolism of cinobufagin in rat liver microsomes. Identification of epimerized and deacetylated metabolites by liquid chromatography/mass spectrometry. Drug Metab. Dispos. 19:917-919.
33. Zhang, L. S., K. Nakaya, T. Yoshida, and Y. Kuroiwa. 1992. Induction by bufalin of differentiation of human leukemia cells HL60, U937, and ML1 toward macrophage/monocyte-like cells and its potent synergistic effect on the differentiation of human leukemia cells in combination with other inducers. Cancer Res. 52:4634-4641.